Development of the Human Pancreas From Foregut to Endocrine Commitment

  1. Neil A. Hanley1,2
  1. 1Centre for Endocrinology and Diabetes, Institute of Human Development, Faculty of Medical & Human Sciences, Manchester Academic Health Sciences Centre, University of Manchester, Manchester, U.K.
  2. 2Endocrinology Department, Central Manchester University Hospitals National Health Service Foundation Trust, Manchester, U.K.
  3. 3Centre for Human Development, Stem Cells and Regeneration, Human Genetics, University of Southampton, Southampton General Hospital, Southampton, U.K.
  1. Corresponding author: Neil A. Hanley, neil.hanley{at}manchester.ac.uk.

Abstract

Knowledge of human pancreas development underpins our interpretation and exploitation of human pluripotent stem cell (PSC) differentiation toward a β-cell fate. However, almost no information exists on the early events of human pancreatic specification in the distal foregut, bud formation, and early development. Here, we have studied the expression profiles of key lineage-specific markers to understand differentiation and morphogenetic events during human pancreas development. The notochord was adjacent to the dorsal foregut endoderm during the fourth week of development before pancreatic duodenal homeobox-1 detection. In contrast to the published data from mouse embryos, during human pancreas development, we detected only a single-phase of Neurogenin 3 (NEUROG3) expression and endocrine differentiation from approximately 8 weeks, before which Nirenberg and Kim homeobox 2.2 (NKX2.2) was not observed in the pancreatic progenitor cell population. In addition to revealing a number of disparities in timing between human and mouse development, these data, directly assembled from human tissue, allow combinations of transcription factors to define sequential stages and differentiating pancreatic cell types. The data are anticipated to provide a useful reference point for stem cell researchers looking to differentiate human PSCs in vitro toward the pancreatic β-cell so as to model human development or enable drug discovery and potential cell therapy.

Footnotes

  • Received October 25, 2012.
  • Accepted April 20, 2013.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

| Table of Contents

This Article

  1. Diabetes vol. 62 no. 10 3514-3522
  1. Supplementary Data
  2. All Versions of this Article:
    1. db12-1479v1
    2. 62/10/3514 most recent